Formulation and characterization of a compacted multiparticulate system for modified release of water-soluble drugs--Part II theophylline and cimetidine.
The purpose was to investigate the effectiveness of an ethylcellulose (EC) bead matrix and different film-coating polymers in delaying drug release from compacted multiparticulate systems. Formulations containing theophylline or cimetidine granulated with Eudragit RS 30D were developed and beads were produced by extrusion-spheronization. Drug beads were coated using 15% wt/wt Surelease or Eudragit NE 30D and were evaluated for true density, particle size, and sphericity. Lipid-based placebo beads and drug beads were blended together and compacted on an instrumented Stokes B2 rotary tablet press. Although placebo beads were significantly less spherical, their true density of 1.21 g/cm(3) and size of 855 mum were quite close to Surelease-coated drug beads. Curing improved the crushing strength and friability values for theophylline tablets containing Surelease-coated beads; 5.7 +/- 1.0 kP and 0.26 +/- 0.07%, respectively. Dissolution profiles showed that the EC matrix only provided 3 h of drug release. Although tablets containing Surelease-coated theophylline beads released drug fastest overall (t(44.2%) = 8 h), profiles showed that coating damage was still minimal. Size and density differences indicated a minimal segregation potential during tableting for blends containing Surelease-coated drug beads. Although modified release profiles >8 h were achievable in tablets for both drugs using either coating polymer, Surelease-coated theophylline beads released drug fastest overall. This is likely because of the increased solubility of theophylline and the intrinsic properties of the Surelease films. Furthermore, the lipid-based placebos served as effective cushioning agents by protecting coating integrity of drug beads under a number of different conditions while tableting.
Cantor
Stuart L
SL
ICON Development Solutions, Ellicott City, MD, USA.
Hoag
Stephen W
SW
Augsburger
Larry L
LL
D000465:Algorithms; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000737:chemistry*; D002482:Cellulose / Q000031:analogs & derivatives; D002626:Chemistry, Pharmaceutical; D002927:Cimetidine / Q000008:administration & dosage / Q000737:chemistry*; D004339:Drug Compounding; D005079:Excipients; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000737:chemistry*; D006813:Humidity; D007700:Kinetics; D008055:Lipids / Q000737:chemistry; D010316:Particle Size; D052638:Particulate Matter; D011109:Polymethacrylic Acids; D012995:Solubility; D013607:Tablets; D013806:Theophylline / Q000008:administration & dosage / Q000737:chemistry*; D014867:Water / Q000737:chemistry
D001993:Bronchodilator Agents; D005079:Excipients; D006635:Histamine H2 Antagonists; D008055:Lipids; D052638:Particulate Matter; D011109:Polymethacrylic Acids; D013607:Tablets; D014867:Water; C038300:methylmethacrylate-methacrylic acid copolymer; C013517:ethyl cellulose; D002927:Cimetidine; D002482:Cellulose; D013806:Theophylline